Overall and event-free survival by patient group
| Patient group . | Overall survival,3-year % (95% CI) . | Event-free survival,3-year % (95% CI) . |
|---|---|---|
| All | 60 (51-71) | 40 (31-52) |
| Donor graft | ||
| Related | 70 (58-83) | 47 (35-63) |
| Unrelated | 47 (33-67) | 32 (20-52) |
| Diagnosis | ||
| Lymphoid | 69 (58-82) | 42 (30-56) |
| Myeloid | 47 (33-67) | 40 (27-59) |
| Age | ||
| Lymphoid | ||
| < 55 y | 65 (51-82) | 42 (29-61) |
| ≤ 55 y | 80 (61-100) | 41 (22-78) |
| Myeloid | ||
| < 55 y | 47 (29-78) | 30 (15-59) |
| ≤ 55 y* | 48 (31-76) | 49 (32-75) |
| Disease status at the start of conditioning | ||
| Non-Hodgkin lymphoma | ||
| CR | 92 (79-100) | 36 (13-96) |
| PR | 76 (63-92) | 53 (38-73) |
| SD or PD* | 0 | 12 (2-78) |
| De novo AML | ||
| CR1 | 50 (33-77) | 48 (31-73) |
| CR2 | 37 (14-100) | 50 (27-93) |
| Other† | 20 (3-100) | 0 |
| Chimerism | ||
| NHL in CR or PR at start of TLI and ATG | ||
| Complete donor chimerism | 81 (69-93) | 74 (57-91) |
| Mixed donor chimerism | 72 (36-100) | 0 |
| De novo AML in CR1 or CR2 at start of TLI and ATG | ||
| Complete donor chimerism | 64 (42-86) | 64 (43-84) |
| Mixed donor chimerism | 25 (0-55) | 25 (0-56) |
| Primary graft failure | 0 | 0 |
| Prior autologous HCT | ||
| NHL with prior autologous HCT | 75 (58-95) | 41 (25-69) |
| NHL without prior autologous HCT | 73 (56-95) | 46 (27-76) |
| Patient group . | Overall survival,3-year % (95% CI) . | Event-free survival,3-year % (95% CI) . |
|---|---|---|
| All | 60 (51-71) | 40 (31-52) |
| Donor graft | ||
| Related | 70 (58-83) | 47 (35-63) |
| Unrelated | 47 (33-67) | 32 (20-52) |
| Diagnosis | ||
| Lymphoid | 69 (58-82) | 42 (30-56) |
| Myeloid | 47 (33-67) | 40 (27-59) |
| Age | ||
| Lymphoid | ||
| < 55 y | 65 (51-82) | 42 (29-61) |
| ≤ 55 y | 80 (61-100) | 41 (22-78) |
| Myeloid | ||
| < 55 y | 47 (29-78) | 30 (15-59) |
| ≤ 55 y* | 48 (31-76) | 49 (32-75) |
| Disease status at the start of conditioning | ||
| Non-Hodgkin lymphoma | ||
| CR | 92 (79-100) | 36 (13-96) |
| PR | 76 (63-92) | 53 (38-73) |
| SD or PD* | 0 | 12 (2-78) |
| De novo AML | ||
| CR1 | 50 (33-77) | 48 (31-73) |
| CR2 | 37 (14-100) | 50 (27-93) |
| Other† | 20 (3-100) | 0 |
| Chimerism | ||
| NHL in CR or PR at start of TLI and ATG | ||
| Complete donor chimerism | 81 (69-93) | 74 (57-91) |
| Mixed donor chimerism | 72 (36-100) | 0 |
| De novo AML in CR1 or CR2 at start of TLI and ATG | ||
| Complete donor chimerism | 64 (42-86) | 64 (43-84) |
| Mixed donor chimerism | 25 (0-55) | 25 (0-56) |
| Primary graft failure | 0 | 0 |
| Prior autologous HCT | ||
| NHL with prior autologous HCT | 75 (58-95) | 41 (25-69) |
| NHL without prior autologous HCT | 73 (56-95) | 46 (27-76) |
CI indicates confidence interval; HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CR, complete remission; PR, partial remission; SD, stable disease; and PD, progressive disease.
The OS falls below the EFS as an artifact of censoring subject(s) between the times of another subject's relapse and death.
Other, beyond 2nd CR, partial response, stable disease, or progressive disease.